Growth strong, profit misses — capex drag and raw material headwind

Delivered 20.7% YoY revenue growth to ₹110.2 Cr

Standalone domestic growth confirmed at 17% YoY

Revenue up 20.7% but net loss -₹1.4 Cr (NPM -1.2%); contradicts opening optimism

Confirmed 29% export growth; analyst noted shipment timing benefit (timing risk acknowledged)

Standalone gross margin 67.1%, down from typical 70%+ levels; OPM 23.6%

Cash profit confirmed at ₹25.6 Cr, +18% YoY

Delayed from prior H1 FY27 guidance; now Q2/H3; revenue contribution starting H2

Management hedged: 'similar to Q1 if input costs persist'; no clear improvement target

Prior guidance: full commercial by Q1 FY'27 start. Now: Q2 trials, H2 revenue. Sheer scale and supplier dependencies cited; minor delay but pushes contribution to H2 FY'27+.

Prior: >65% gross margin sustained. Delivered: 67.1% gross, 23.6% OPM. Within prior range but compressed; management confirmed volatility will persist.

Prior: Q1 ~Q4 FY26 levels. Delivered: Q1 net loss, no profit target given for FY'27. Management says 'will remain relatively moderate in FY'27' due to capex costs.

First quantified guide for new product portfolio (cell culture, bioprocess, specialized pharma). Panchla+Amta to be 20–25% of FY'28 standalone revenue.

Interest run rate ₹20 Cr/year; will decline post-FY'27. Helps explain Q1 net loss and tempered FY'27 profit outlook.

Sheer scale, volume of machines, external engineering dependencies, supplier challenges normal for projects of this size; multiple lines still undergoing trials.

Very volatile; peaked 6 weeks ago, sharp 10-day drop, now rising again. Marginal price hikes in India; near-zero internationally, relying on rupee depreciation. Can't cover full cost impact.

Difficult to call; external environment (RM costs) is driver, not internal operations. Depends on week-to-week RM trends.

No exact breakdown given; most Panchla revenue from existing products or capacity expansions moved there. No cell culture revenue yet; bioprocess containers (media, roller bottles) contributed.

₹160 Cr CWIP + ₹20 Cr capital advances remain. Completion within Q2–Q3; no major capex beyond this in FY'27.

₹400 Cr incremental revenue over existing capacity; total peak ~₹750–800 Cr (not ₹900 Cr as analyst suggested).

Depreciation will peak in FY'27 at ₹105–110 Cr full-year. Interest run rate ₹20 Cr/year in FY'27, declining in FY'28.

Huge benefit of shipments; buyer-nominated timing beyond company control. Could have bad export quarters ahead due to vessel availability and West Asia issues.

15% is base from existing products + market growth; new products (cell culture, bioprocess) could add 5–7% for 20%+ total. But cell culture is sensitive, needs sustainable approach.

Target 20–25% of standalone revenue from Panchla+Amta in FY'28.

₹65–70 Cr from entire new product portfolio (cell culture included), not broken out separately.

Certain hikes taken but small vs. total cost impact, domestic only. Not quantified by percentage due to spread across thousands of invoices/customers.

Cell culture is sensitive, heavily established. Focus on sustainable growth, not aggressive ramp. New products can drive 5–7% incremental growth for 20%+ total.

Challenging. Tariffs rumors, high input costs in India. Maintaining prices, using rupee depreciation for partial offset. Focus on building base, not margins, for now.

Nerbe: 70% Germany domestic, 30% EU rest. Growth opportunity in geographic expansion outside Germany and product portfolio expansion from Tarsons.

Government market: 15–20% of ₹1,300 Cr domestic market. GEM portal brought down volumes (research institutes abolished rate contracts, now bid via GEM each time).

Q1 +20.7%, likely 15%+ achievable for FY'27 on base growth + export recovery. Hedged on international environment.

Facilities ramp H2 FY'27; full ramp FY'28. If base standalone ₹350 Cr, new facilities = ₹70–87 Cr.

Cell culture + bioprocess + specialized pharma. Lumpsum target; cell culture alone TBD.

Heavily hedged: '7–7.5 months left; external environment volatile.' Depends on RM cost trend.

Delivered 67.1% Q1. Sustained by partial pricing + mix shift. Not a floor; volatility expected.

Mechanism clear but unproven. Timing depends on new product commercial ramp and price stability.

Most 4-year program complete. Remaining spend on capex closeout and commissioning trials.

Focus shifts from capacity creation to utilization. Maintenance CAPEX ₹20–25 Cr/year expected.

RM costs up 25–50% in Q1; peaked 6w ago, now rising again. Pricing power insufficient (partial price hikes only). Gross margin 67.1% down from 70%+. Q1 only 500bp hit; further escalation would compress EBITDA below 23%.

Panchla commissioning delayed from H1 to Q2/H2 FY'27; trial runs ongoing. If commercial ramp slips further or demand not materializes, capex ROI erodes. Management targeting ₹750–800 Cr peak revenue; currently ₹110 Cr standalone (need ~7x growth over 3–4 years).

Cell culture is described as 'sensitive product line' with 'many established players' and 'highly moated market.' Tarsons is entrant; expects 2–3 year ramp to meaningful scale. Bioprocess bottles took time to scale; cell culture could be 2–3x longer. FY'28 target ₹65–70 Cr (all new products) is lumpsum; cell culture portion unknown. Management candid: growth beyond 15% depends heavily on cell culture success.

Export growth 29% in Q1 benefited from 'huge benefit of shipments' (buyer-nominated timing). West Asia disruptions and vessel availability cited as volatility driver. Tariff rumors (US 10% already in effect, more feared). Analyst flagged risk of 'bad export quarter' in Q2 or Q3 due to timing reversals. Management relying on rupee depreciation for export realizations, not pricing.

Net PAT -₹1.4 Cr Q1 due to ₹24.5 Cr depreciation (Panchla +Amta) + ₹20 Cr interest. Depreciation peaking at ₹105–110 Cr full-year FY'27. Even if EBITDA holds at 23.6%, net profit will be muted through FY'27. Interest to decline only post-FY'27. Not until FY'28–FY'29 should net profit inflect upward with capacity utilization and reduced capex costs.

Nerbe grew only +6% YoY (constant currency) in Q1. Described as 'strategic buyout'; expected to deliver 'larger years' of growth but 'not consistent.' Majority business (70%) concentrated in Germany; 95% of rest in EU. Potential to cross-sell Tarsons products and expand geography, but execution risk remains. Management noted limited sales team growth over past 1.5 years; focus on quality of hires over headcount.